Cure8
Patient treatment engagement scale (PTES) for inflammatory bowel disease: exploring background factors.
BMC research notes

Cure8 research brief

Patient treatment engagement scale (PTES) for inflammatory bowel disease: exploring background factors.

2 min read
Research and clinical trials Clinical study Clinicians Researchers Patients On Biologics Adult patients Parents Caregivers Newly Diagnosed

Why This Matters

Patient engagement in treatment decisions can affect satisfaction, adherence, and care planning. This study identifies practical factors (treatment options, trusted providers, community support) associated with higher engagement scores in people with IBD.

Who Should Pay Attention

Clinicians and care teams treating adults with IBD (UC and Crohn's), patient advocates and support-group organizers, researchers studying shared decision-making and patient-reported engagement.

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

The researchers used a web-based questionnaire and regression analysis to explore which background factors correlate with PTES scores. Key positive associations included number of available treatment options, presence of complications, trust in the attending physician, number of trusted healthcare professionals, and availability of supportive communities.

Subgroup analysis suggested the number of treatment options had a larger influence for ulcerative colitis patients, while having more trusted healthcare professionals mattered more for Crohn’s disease patients.

Practical takeaway: The paper supports the idea that offering patients clear choices and building trust with care teams are linked with greater patient engagement. This may be useful when clinicians and care teams design consultations and support resources for people with IBD.

Keep In Mind

Structured content depth is abstract: the supplied text is an abstract from a journal article (BMC Research Notes). The study used a web questionnaire and regression analysis; this brief summarizes the abstract and does not reflect a full-text review of the complete paper.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationBMC research notes
AuthorsHisao Toyoshima, Chiharu Yashima, Tomohide Akase +1 more
InstitutionPharmacy Management Institute, Graduate School of Business, Japan University of Economics, 25-17 Sakuragaokacho, Shibuya-Ku, Tokyo, Japan. toyoshima.hisao@gmail.com.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 21, 2026, 12:00 AM
Content availableJournal abstract

Conflict statement: Declarations. Ethics approval and consent to participate: Ethics approval was obtained from the Research Ethics Committee, Japan University of Economics (Approval number: 2022-0328-02). The survey was conducted with consent interpreted as having been obtained with the submission of responses. Consent for publications: Not applicable. Competing interests: The authors declare no competing interests.

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →